Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials.

AIMS To assess the effect of statins on a range of health outcomes. METHODS We undertook a population-based cohort study to assess the effect of statins on a range of health outcomes using a propensity score-based method to control for differences between people prescribed and not prescribed statins. We validated our design by comparing our results for vascular outcomes with the effects established in large randomized trials. The study was based on the United Kingdom Health Improvement Network database that includes the computerized medical records of over four and a half million patients. RESULTS People who initiated treatment with a statin (n = 129,288) were compared with a matched sample of 600,241 people who did not initiate treatment, with a median follow-up period of 4.4 years. Statin use was not associated with an effect on a wide range of outcomes, including infections, fractures, venous thromboembolism, gastrointestinal haemorrhage, or on specific eye, neurological or autoimmune diseases. A protective effect against dementia was observed (hazard ratio 0.80, 99% confidence interval 0.68, 0.95). There was no effect on the risk of cancer even after > or =8 years of follow-up. The effect sizes for statins on vascular end-points and mortality were comparable to those observed in large randomized trials, suggesting bias and confounding had been well controlled for. CONCLUSIONS We found little evidence to support wide-ranging effects of statins on health outcomes beyond their established beneficial effect on vascular disease.

[1]  J. Armitage,et al.  The safety of statins in clinical practice , 2007, The Lancet.

[2]  A. Ferrara,et al.  Medical therapy for diabetes is associated with increased use of lower endoscopy , 2007, Pharmacoepidemiology and drug safety.

[3]  P. Macfarlane,et al.  Long-term follow-up of the West of Scotland Coronary Prevention Study. , 2007, The New England journal of medicine.

[4]  E. B. Larson,et al.  Statin Therapy Is Associated with Reduced Neuropathologic Changes Statin Therapy Is Associated with Reduced Neuropathologic Changes of Alzheimer Disease , 2022 .

[5]  J. Avorn,et al.  Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. , 2007, American journal of epidemiology.

[6]  R. Karas,et al.  Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. , 2007, Journal of the American College of Cardiology.

[7]  Lewis E Kazis,et al.  Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.

[8]  S. Hernández-Díaz,et al.  Statins and fracture risk. A systematic review , 2007, Pharmacoepidemiology and drug safety.

[9]  W. Bilker,et al.  Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research , 2007, Pharmacoepidemiology and drug safety.

[10]  Richard M. Martin,et al.  Statins and risk of cancer: A systematic review and metaanalysis , 2007, International journal of cancer.

[11]  B. Noël.  Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  R. Thomsen.  The lesser known effects of statins , 2006, BMJ : British Medical Journal.

[13]  F. McAlister,et al.  Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study , 2006, BMJ : British Medical Journal.

[14]  Frank de Vries,et al.  Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. , 2006, International journal of epidemiology.

[15]  O. Selnes,et al.  Vascular cognitive impairment , 2006, Nature Clinical Practice Neurology.

[16]  Sebastian Schneeweiss,et al.  Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. , 2006, Journal of clinical epidemiology.

[17]  D. Fedson.  Pandemic Influenza: A Potential Role for Statins in Treatment and Prophylaxis , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  U. Ravnskov,et al.  Should we lower cholesterol as much as possible? , 2006, BMJ : British Medical Journal.

[19]  Til Stürmer,et al.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. , 2006, Journal of clinical epidemiology.

[20]  R. Rosenson,et al.  Statins: panacea for sepsis? , 2006, The Lancet. Infectious diseases.

[21]  Ping Li,et al.  Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis , 2006, The Lancet.

[22]  M. Pillinger,et al.  Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? , 2006, Arthritis and rheumatism.

[23]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[24]  J. Liao.  Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. , 2005, The American journal of cardiology.

[25]  L. Smeeth,et al.  A case control study of age related macular degeneration and use of statins , 2005, British Journal of Ophthalmology.

[26]  Lewis H Kuller,et al.  Statin use and the risk of incident dementia: the Cardiovascular Health Study. , 2005, Archives of neurology.

[27]  Ronit Almog,et al.  Statins and the risk of colorectal cancer. , 2005, The New England journal of medicine.

[28]  D. Sparks,et al.  Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. , 2005, Archives of general psychiatry.

[29]  R. Abbott,et al.  Disorder resembling Guillain–Barré syndrome on initiation of statin therapy , 2004, Muscle & nerve.

[30]  A. Bourke,et al.  Feasibility study and methodology to create a quality-evaluated database of primary care data. , 2004, Informatics in primary care.

[31]  F. Sundram,et al.  Thrombotic thrombocytopenic purpura associated with statin treatment , 2004, Postgraduate Medical Journal.

[32]  R. Madhok,et al.  Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial , 2004, The Lancet.

[33]  M. Namazi.  Statins: novel additions to the dermatologic arsenal? , 2004, Experimental dermatology.

[34]  C. Polman,et al.  Statins for the treatment of multiple sclerosis: cautious hope , 2004, The Lancet.

[35]  A. Evans,et al.  Zosteriform metastasis from melanoma , 2003, BMJ : British Medical Journal.

[36]  L. Smeeth,et al.  Cataract and the use of statins: a case-control study. , 2003, QJM : monthly journal of the Association of Physicians.

[37]  Corri Black,et al.  Validity of the General Practice Research Database , 2003, Pharmacotherapy.

[38]  S. Evans.  Commentary: Matched cohorts can be useful. , 2003, BMJ.

[39]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[40]  A. Segal.  Alopecia associated with atorvastatin. , 2002, The American journal of medicine.

[41]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[42]  E. Vittinghoff,et al.  Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS) , 2002, Circulation.

[43]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[44]  H. Syddall,et al.  Risk of macular degeneration in users of statins: cross sectional study , 2001, BMJ : British Medical Journal.

[45]  A. Laupacis,et al.  Use of statins and the subsequent development of deep vein thrombosis. , 2001, Archives of internal medicine.

[46]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[47]  J. Avorn,et al.  HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. , 2000, JAMA.

[48]  H Jick,et al.  HMG-CoA reductase inhibitors and the risk of fractures. , 2000, JAMA.

[49]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[50]  M. Robbins,et al.  Lovastatin-induced hemolytic anemia: not a class-specific reaction. , 1995, American Journal of Medicine.

[51]  I. Edwards,et al.  Statins, Neuromuscular Degenerative Disease and an Amyotrophic Lateral Sclerosis-Like Syndrome , 2007, Drug safety.

[52]  W. Howard.  Statin Use and Incident Nuclear Cataract , 2007 .

[53]  P. Loehrer.  Statins and Cancer Risk: A Meta-analysis , 2007 .

[54]  Sonal Singh,et al.  Statins and Pancreatitis , 2006, Drug safety.

[55]  H. Jick,et al.  Statins and the risk of idiopathic venous thromboembolism. , 2002, British journal of clinical pharmacology.

[56]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .